Elyse A Linson1, Stephen B Hanauer2. 1. Northwestern Memorial Hospital, 250 E Huron Street, Chicago, IL, 60611, USA. Elyse.linson@northwestern.edu. 2. Feinberg School of Medicine, Northwestern University, 676 N Saint Clair, Chicago, IL, 60611, USA.
Abstract
PURPOSE OF REVIEW: To update changes in the epidemiology of colorectal cancer in patients with ulcerative colitis and Crohn's disease over the past decades. RECENT FINDINGS: Since the mid twentieth century, studies have found that the incidence of colorectal cancer in patients with IBD has been greater than that of the general population, especially for patients with a family history of colorectal cancer, a diagnosis of primary sclerosing cholangitis, and/or pancolitis. While Crohn's disease and ulcerative colitis are still associated with a risk of colorectal cancer, current treatment approaches and surveillance measures have markedly reduced the risk according to population-based cohort studies such that the risk is now more comparable to that of the general population. It is predicted that by 2025, more than two million patients will be living with inflammatory bowel disease in the United States. As advanced treatment options become available to achieve histologic remissions and as surveillance techniques to detect neoplasia improve, guidelines for surveillance will continue to evolve.
PURPOSE OF REVIEW: To update changes in the epidemiology of colorectal cancer in patients with ulcerative colitis and Crohn's disease over the past decades. RECENT FINDINGS: Since the mid twentieth century, studies have found that the incidence of colorectal cancer in patients with IBD has been greater than that of the general population, especially for patients with a family history of colorectal cancer, a diagnosis of primary sclerosing cholangitis, and/or pancolitis. While Crohn's disease and ulcerative colitis are still associated with a risk of colorectal cancer, current treatment approaches and surveillance measures have markedly reduced the risk according to population-based cohort studies such that the risk is now more comparable to that of the general population. It is predicted that by 2025, more than two million patients will be living with inflammatory bowel disease in the United States. As advanced treatment options become available to achieve histologic remissions and as surveillance techniques to detect neoplasia improve, guidelines for surveillance will continue to evolve.
Authors: S Bonovas; G Fiorino; T Lytras; G Nikolopoulos; L Peyrin-Biroulet; S Danese Journal: Aliment Pharmacol Ther Date: 2017-03-06 Impact factor: 8.171